<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic treatment of infection due to &lt;em&gt;Vibrio vulnificus&lt;/em&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic treatment of infection due to <em>Vibrio vulnificus</em></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic treatment of infection due to <em>Vibrio vulnificus</em></div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Adults</td> <td class="subtitle1_left">Children</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Patients with either: <ul> <li>Severe infection: Primary sepsis or serious wound infection</li> <li>Mild wound infection, in the presence of risk factors for severe disease<sup>*</sup></li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong>A third- or fourth-generation cephalosporin</strong> (one of the following):</td> </tr> <tr> <td class="indent2">Ceftriaxone</td> <td>1 to 2 g IV every 24 hours</td> <td>50 to 75 mg/kg IV every 24 hours (maximum 2 g/day)</td> </tr> <tr> <td class="indent2">Cefotaxime</td> <td>2 g IV every 6 to 8 hours</td> <td>50 mg/kg IV every 6 to 8 hours (maximum 8 g/day)</td> </tr> <tr> <td class="indent2">Ceftazidime</td> <td>1 to 2 g IV every 8 hours</td> <td>50 mg/kg IV every 8 hours (maximum 6 g/day)</td> </tr> <tr> <td class="indent2">Cefepime</td> <td>2 g IV every 12 hours</td> <td>50 mg/kg IV every 12 hours (maximum 4 g/day)</td> </tr> <tr> <td class="indent3" colspan="3"><strong class="heading">plus either</strong></td> </tr> <tr> <td class="indent1" colspan="3"><strong>A tetracycline</strong> (preferred; one of the following)<sup>¶</sup></td> </tr> <tr> <td class="indent2">Doxycycline</td> <td>100 mg IV or orally every 12 hours</td> <td>2.2 mg/kg IV or orally every 12 hours (maximum 100 mg/dose)</td> </tr> <tr> <td class="indent2">Minocycline</td> <td>100 mg IV or orally every 12 hours</td> <td>2 mg/kg IV or orally every 12 hours (maximum 100 mg/dose)</td> </tr> <tr> <td class="indent3" colspan="3"><strong class="heading">or</strong></td> </tr> <tr> <td class="indent1" colspan="3"><strong>A fluroquinolone</strong> (alternative agent; one of the following)<sup>Δ◊</sup></td> </tr> <tr> <td class="indent2">Ciprofloxacin</td> <td>400 mg IV twice daily or 500 to 750 mg orally every 12 hours</td> <td> <p><strong>IV:</strong> 10 mg/kg every 12 hours (maximum 400 mg per/dose)</p> <strong>Oral:</strong> 10 to 20 mg/kg every 12 hours (maximum 750 mg/dose)</td> </tr> <tr> <td class="indent2">Levofloxacin</td> <td>750 mg IV or orally once daily</td> <td> <p><strong>6 months to 5 years:</strong> 8 to 10 mg/kg IV or orally every 12 hours (maximum 750 mg/day)</p> <strong>≥5 years:</strong> 10 mg/kg IV or orally once daily (maximum 750 mg/day)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Patients with mild wound infection, in the absence of risk factors for severe disease<sup>*</sup></td> </tr> <tr> <td class="indent1" colspan="3"><strong>A tetracycline</strong> (preferred; one of the following)<sup>¶</sup></td> </tr> <tr> <td class="indent2">Doxycycline</td> <td>100 mg orally twice daily</td> <td>2.2 mg/kg orally every 12 hours (maximum 100 mg/dose)</td> </tr> <tr> <td class="indent2">Minocycline</td> <td>100 mg orally twice daily</td> <td>2 mg/kg orally every 12 hours (maximum 100 mg/dose)</td> </tr> <tr> <td class="indent3" colspan="3"><strong class="heading">or</strong></td> </tr> <tr> <td class="indent1" colspan="3"><strong>A fluroquinolone</strong> (alternative agent; one of the following)<sup>Δ◊</sup></td> </tr> <tr> <td class="indent2">Ciprofloxacin</td> <td>500 mg orally twice daily</td> <td>10 mg/kg orally every 12 hours (maximum 500 mg/dose)</td> </tr> <tr> <td class="indent2">Levofloxacin</td> <td>750 mg orally once daily</td> <td> <p><strong>6 months to 5 years:</strong> 8 to 10 mg/kg orally every 12 hours (maximum 750 mg/day)</p> <strong>≥5 years:</strong> 10 mg/kg orally once daily (maximum 750 mg/day)</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is for use in conjunction with UpToDate content on treatment of infection due to <em>Vibrio vulnificus</em>. The doses listed are intended for patients with normal kidney function; the doses of some of these agents must be adjusted in patients with reduced kidney function. Refer to the Lexicomp drug-specific monographs within UpToDate for dose adjustments.</div><div class="graphic_footnotes"><p>IV: intravenously.</p>
<p>* Risk factors for severe disease include alcoholic cirrhosis, underlying liver disease including chronic hepatitis due to alcohol or other causes, moderate to heavy alcohol use (in the absence of documented liver disease), hereditary hemochromatosis, and chronic diseases (such as diabetes, thalassemia, renal failure, and immunocompromising conditions).</p>
<p>¶ Doxycycline can be administered for short durations (≤21 days) without regard to patient age<sup>[1]</sup>.</p>
<p>Δ For patients who are not able to tolerate tetracyclines, a fluoroquinolone may be used as an alternative agent; we prefer ciprofloxacin, given limited clinical data for other fluoroquinolones.</p>
◊ Fluoroquinolones should not be used routinely as first-line agents in children &lt;18 years of age except in specific conditions for which there are no alternative agents and the drug is known to be effective<sup>[2]</sup>.</div><div class="graphic_reference"><p>Includes data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p>
References:
<ol>
<li>American Academy of Pediatrics. Tetracyclines. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, KimberlinDW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021.</li>
<li>American Academy of Pediatrics. Fluoroquinolones. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, KimberlinDW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021.</li>
</ol></div><div id="graphicVersion">Graphic 143005 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
